These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20402173)

  • 1. Activated recombinant factor VII (rFVIIa).
    Grottke O; Henzler D; Rossaint R
    Best Pract Res Clin Anaesthesiol; 2010 Mar; 24(1):95-106. PubMed ID: 20402173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
    Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recombinant activated factor VII for perioperative bleeding].
    López R; Aeschlimann N; Carvajal C; Lema G
    Rev Med Chil; 2009 Jun; 137(6):837-43. PubMed ID: 19746288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
    Brady KM; Easley RB; Tobias JD
    Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NovoSeven as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S107-11. PubMed ID: 10850574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.
    Hedner U; Glazer S; Falch J
    Transfus Med Rev; 1993 Apr; 7(2):78-83. PubMed ID: 8481602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
    Murkin JM
    Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Stanworth SJ; Birchall J; Doree CJ; Hyde C
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005011. PubMed ID: 17443565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of recombinant factor VIIa in the perioperative period.
    Levi M
    Hamostaseologie; 2009 Jan; 29(1):68-70. PubMed ID: 19151850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
    Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
    Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of recombinant activated FVII in postpartum hemorrhage.
    Franchini M; Franchi M; Bergamini V; Montagnana M; Salvagno GL; Targher G; Lippi G
    Clin Obstet Gynecol; 2010 Mar; 53(1):219-27. PubMed ID: 20142658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.
    Puetz J
    Drug Des Devel Ther; 2010 Jul; 4():127-37. PubMed ID: 20689699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety update on the use of recombinant activated factor VII in approved indications.
    Neufeld EJ; Négrier C; Arkhammar P; Benchikh el Fegoun S; Simonsen MD; Rosholm A; Seremetis S
    Blood Rev; 2015 Jun; 29 Suppl 1():S34-41. PubMed ID: 26073367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.